Volume 44, Issue 4, Pages (April 2006)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Diagnostics in hepatitis C: The end of response-guided therapy?
Volume 62, Issue 2, Pages (February 2015)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Volume 41, Issue 6, Pages (December 2004)
The impact of hepatitis E in the liver transplant setting
Phase 3 Treatment-Naïve and Treatment-Experienced
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Volume 139, Issue 4, Pages (October 2010)
Volume 68, Issue 5, Pages (May 2018)
Julien Bissonnette, Dominique Valla, Pierre-Emmanuel Rautou 
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
The impact of hepatitis E in the liver transplant setting
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 52, Issue 3, Pages (March 2010)
Volume 42, Issue 1, Pages (January 2005)
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Volume 139, Issue 4, Pages (October 2010)
Diagnostics in hepatitis C: The end of response-guided therapy?
Virological tools to diagnose and monitor hepatitis C virus infection
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Living donor liver transplantation: is the hype over?
Volume 59, Issue 4, Pages (October 2013)
Volume 41, Issue 3, Pages (September 2004)
Volume 69, Issue 2, Pages (August 2018)
Volume 41, Issue 3, Pages (September 2004)
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
From non-A, non-B hepatitis to hepatitis C virus cure
Volume 62, Issue 3, Pages (March 2015)
Acute hepatitis C: Current status and remaining challenges
‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?  Andres Duarte-Rojo, Elizabeth Jenny Heathcote,
Management of cirrhosis due to chronic hepatitis C
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Viral load and humoral immune response in association with disease severity in Puumala hantavirus-infected patients—implications for treatment  L. Pettersson,
Volume 62, Issue 1, Pages (January 2015)
Volume 44, Issue 2, Pages (February 2006)
Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients  Vincent G. Bain, Kelly D.
Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C  David R. Nelson, Vinod Rustgi, Vijayan.
Economics of chronic hepatitis B and hepatitis C
Volume 139, Issue 1, Pages e4 (July 2010)
Volume 53, Issue 2, Pages (August 2010)
Volume 50, Issue 4, Pages (April 2009)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Volume 67, Issue 5, Pages (November 2017)
Volume 137, Issue 6, Pages (December 2009)
Phase 3 Treatment-Naïve and Treatment-Experienced
Immigration and viral hepatitis
Treatment failure in hepatitis C: Mechanisms of non-response
HCV targeting of patients with cirrhosis
Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential rather than concomitant administration with pegylated interferon and ribavirin?  Lawrence.
Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection  Yoav Lurie, Regine Rouzier-Panis, George.
Volume 63, Issue 1, Pages (July 2015)
Volume 51, Issue 2, Pages (August 2009)
Chronic hepatitis B in children and adolescents
Pathogenesis of cholestatic hepatitis C
Clinical Gastroenterology and Hepatology
Chimeric mouse model of hepatitis B virus infection
Volume 54, Issue 6, Pages (June 2011)
Volume 60, Issue 5, Pages (May 2014)
Volume 62, Issue 5, Pages (May 2015)
Volume 39, Issue 3, Pages (September 2003)
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Volume 44, Issue 4, Pages 671-678 (April 2006) A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients  Vincent G. Bain, Kelly D. Kaita, Eric M. Yoshida, Mark G. Swain, E. Jenny Heathcote, Avidan U. Neumann, Michele Fiscella, Ren Yu, Blaire L. Osborn, Patrick W. Cronin, William W. Freimuth, John G. McHutchison, G. Mani Subramanian  Journal of Hepatology  Volume 44, Issue 4, Pages 671-678 (April 2006) DOI: 10.1016/j.jhep.2005.12.011 Copyright © 2006 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Mean HCV RNA reduction and proportion of patients with ≥2 log10 IU/mL reduction (in parenthesis) in HCV RNA at Day 28. Journal of Hepatology 2006 44, 671-678DOI: (10.1016/j.jhep.2005.12.011) Copyright © 2006 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Mean HCV RNA (log10 IU/mL) change from baseline. The study duration of 42 days allowed assessment of antiviral response 28 days following the second injection of alb-IFN administered on Day 14 (vertical line). Journal of Hepatology 2006 44, 671-678DOI: (10.1016/j.jhep.2005.12.011) Copyright © 2006 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Box plot of HCV RNA reduction (log10 IU/mL) at Week 4 by body mass index in kg/m2 (BMI) and treatment group. Journal of Hepatology 2006 44, 671-678DOI: (10.1016/j.jhep.2005.12.011) Copyright © 2006 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Biphasic viral kinetics. Panel A: First phase HCV RNA reduction (log10 IU/mL) in the low dose (200–670μg) or high dose (900–1200μg) treatment groups is represented. The mean (±SD) HCV RNA reduction (horizontal bar) for the low dose and high dose groups is provided. The dashed line represents the clinically significant first-phase response (HCV RNA reduction of >0.5 log10 IU/mL). Panel B: Second-phase HCV RNA reduction slope (log10 IU/mL) in the low-dose (200–670μg) or high-dose (900–1200μg) treatment groups is represented. The mean (± SD) HCV RNA reduction (horizontal bar) for the low- and high-dose groups is provided. The dashed line represents the clinically significant second-phase slope of 0.3 log/wk. Journal of Hepatology 2006 44, 671-678DOI: (10.1016/j.jhep.2005.12.011) Copyright © 2006 European Association for the Study of the Liver Terms and Conditions

Fig. 5 Mean (± SD) serum albumin-interferon alfa concentrations. Journal of Hepatology 2006 44, 671-678DOI: (10.1016/j.jhep.2005.12.011) Copyright © 2006 European Association for the Study of the Liver Terms and Conditions

Fig. 6 Frequency (panel A) and median duration (panel B) of most common adverse events following the first and second injections of albumin-interferon alfa. Journal of Hepatology 2006 44, 671-678DOI: (10.1016/j.jhep.2005.12.011) Copyright © 2006 European Association for the Study of the Liver Terms and Conditions

Fig. 7 Percent change from baseline in absolute neutrophil counts (panel A) and platelet counts (panel B). Journal of Hepatology 2006 44, 671-678DOI: (10.1016/j.jhep.2005.12.011) Copyright © 2006 European Association for the Study of the Liver Terms and Conditions